AA
AKBA icon

AlphaMark Advisors’s Akebia Therapeutics AKBA Stock Holding History

AlphaMark Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$73K Buy
+38,461
New +$66.8K 0.03% 208

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AlphaMark Advisors's AKBA Position: Q4 2024 in Review

AlphaMark Advisors opened a new position in Akebia Therapeutics (AKBA) in Q4 2024: 38,461 shares worth $73K. The stake represents 0.03% of the portfolio and ranks #208 among its holdings.

121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • AlphaMark Advisors held 38,461 shares of Akebia Therapeutics worth $73K as of Q4 2024.
  • Akebia Therapeutics was a new AlphaMark Advisors position in Q4 2024.
  • Akebia Therapeutics made up 0.03% of AlphaMark Advisors's portfolio in Q4 2024, its #208 holding.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.